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Résumé en
anglais
Androgen-deprivation therapy (ADT) in patients with prostate cancer can be achieved
surgically or chemically, notably by prescribing LHRH analogs. Major bone loss occurs
rapidly in both cases, due to the decrease in testosterone levels, and can increase the
fracture risk. The objective of developing these recommendations was to achieve a
practical consensus among various scientific societies, based on a literature review,
about osteoporosis prevention and treatment in patients on ADT. The following
scientific societies contributed to the work: Société Française de Rhumatologie (SFR),
Groupe de Recherche et d’Information sur les Ostéoporoses (GRIO), Groupe Européen
d’Etudes des Métastases Osseuses (GEMO), Association Francophone pour les SOins
de Support (AFSOS), Association Française d’Urologie (AFU), Société Française de
Radiothérapie Oncologique (SFRO). Medication prescription and reimbursement
modalities in France were taken into account. The recommendations state that a
fracture-risk evaluation and interventions targeting risk factors for fractures should be
provided to all patients on ADT. Those patients with a history of severe osteoporotic
fracture and/or a T-score <-2.5 should receive osteoporosis therapy. Patients whose T-
score is between -1.5 and -2.5 should be treated if they exhibit at least two other risk
factors among the following: age ≥75 years, history of nonsevere fracture after 50
years of age, body mass index <19 kg/m², at least three comorbidities (e.g.,
cardiovascular disease, depression, Parkinson’s disease, and dementia), current
glucocorticoid therapy, and repeated falls. When the decision is difficult, FRAX® score
determination and an assessment by a bone disease specialist may be helpful. When
osteoporosis therapy is not indicated, general measures should be applied, and bone
mineral density measured again after 12-24 months. The anti-tumor effects of
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